Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The rationale: BPC-157 drives angiogenesis and local repair, while TB-500 supports cell migration and broader soft-tissue regeneration
Retatrutide is currently in Phase 2 clinical trials
compounded under Section 503A pharmacy rules Typical research dose / 250-500 mcg subcutaneous injection once daily Lethal dose in humans / none reported in published literature as of May 2026 GH-receptor activation / absent at standard and supra-pharmacologic doses per Heffernan et al
By selectively inhibiting nicotinamide N-methyltransferase (NNMT), 5-Amino-1MQ helps preserve intracellular NAD+ levels and redirect cellular energy metabolism toward enhanced fat oxidation and mitochondrial efficiency
US$ 23.88
US$ 27.38
US$ 20.83
US$ 28.33
US$ 20.74
